Reviewer's report

Title: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis [NCT00145301]

Version: 3 Date: 28 January 2008

Reviewer: Richard Day

Reviewer's report:

The attention to the hepatotoxicity seen and the discussion of the data is now satisfactory.

What next?: Accept without revision

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have sat on advisory boards for lumiracoxib in Australia, consulted to Novartis on Phase II studies of the drug. Some many years ago I sat on an advisory board for celecoxib in Australia